
Opinion|Videos|April 24, 2025
Genomic Testing in Early-Stage Breast Cancer: Institutional and Multidisciplinary Perspectives
Discover essential insights on breast cancer awareness, prevention, and treatment options to empower your health journey.
Advertisement
Episodes in this series

Approaches to Genomic Testing Implementation
Main Discussion Topics:
- Multidisciplinary approach to genomic testing decisions in early-stage breast cancer
- Timing considerations for test ordering (presurgical core biopsy vs postsurgical specimen)
- Communication approaches with patients regarding testing and results
Key Points for Physicians:
- Genomic testing decisions benefit from multidisciplinary tumor board input involving surgeons, medical oncologists, and pathologists.
- Testing on core biopsy specimens can reduce the time to treatment decisions by 2 to 3 weeks.
- Testing may be unnecessary if a patient has comorbidities precluding chemotherapy or has already declined chemotherapy.
Notable Insights:
- Surgeons often order the genomic tests, but medical oncologists typically use the information to guide treatment decisions.
- Reducing time between diagnosis and treatment plan development addresses patients’ key concerns: “Why did I get this?” and “Will I need chemotherapy?”
Clinical Significance: Effective implementation of genomic testing requires thoughtful coordination between surgical and medical oncology teams, with consideration for patient preferences, and timing that can significantly improve the treatment planning process..
Advertisement
Related to this article

The FDA has approved neladalkib for previously treated, ALK-positive, locally adanced or metastatic non-small cell lung cancer.

Roswell Park researchers found CD83 CAR T cells could overcome CD19-targeted therapy resistance in preclinical models of B-cell cancers.

Ryan J. Sullivan, MD, discusses HLA testing, liver-directed therapy, and emerging targeted and T-cell–based therapies for metastatic uveal melanoma.

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
4
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
5

